NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Up 5.2 %

Shares of NASDAQ NURO opened at $3.93 on Monday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $6.40. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $3.83. The stock has a market capitalization of $7.97 million, a price-to-earnings ratio of -0.62 and a beta of 2.28.

NeuroMetrix (NASDAQ:NURO) last posted its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The business had revenue of $0.77 million for the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.